Skip to main content
Trials logoLink to Trials
. 2024 Mar 11;25:178. doi: 10.1186/s13063-024-07984-3

Correction: Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts

Samyra R Cox 1,2,, Abhay Kadam 3, Sachin Atre 4, Akshay N Gupte 2, Hojoon Sohn 1,5, Nikhil Gupte 2,3, Trupti Sawant 4, Vishal Mhadeshwar 3, Ryan Thompson 1, Emily Kendall 1,2, Christopher Hofmann 1,2, Nishi Suryavanshi 2,3, Deanna Kerrigan 1,6, Srikanth Tripathy 4, Arjunlal Kakrani 4, Madhusudan S Barthwal 4, Vidya Mave 2,3,#, Jonathan E Golub 1,2,#; the TB Aftermath study team
PMCID: PMC10929208  PMID: 38468342

Correction: Trials 23, 635 (2022)

https://doi.org/10.1186/s13063-022-06503-6

Following publication of the original article [1], we have been notified that sputum collection has been done at the TU instead of at home, as originally stated in the paper. This change was made due to logistical constraints. The Interventions and Data collection and management sections have been modified to reflect this.

In the Sample size section, second paragraph, the phrase “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 80% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 3 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” was also modified into “Assuming a rate of 12 TB cases per 100 person-years (…) we are powered at 90% to determine that the TACF arm is non- inferior to the HACF arm with a non-inferiority interval of 1.7 per 100 person-years and a sample size of 1076 index patients and two HHCs per index patient (n = 2152)” (changes marked in bold).

3 was also changed into 1.7 into the Statistical Methods section (“the upper bound of this estimate is less than 1.7 per 100 person-years”). 3 per 100 person-years applied to recurrent cases only. The non-inferiority margin for the primary outcome which includes both new and recurrent cases is 1.7 per 100 person-years.

The author contribution section was also modified to include the statement: “SA and TS resigned from the study and were not involved in the discussion related to the manuscript correction.”

The original article has been corrected.

Footnotes

Vidya Mave and Jonathan E. Golub have equal contributions.

Reference

  • 1.Cox SR, et al. Tuberculosis (TB) Aftermath: study protocol for a hybrid type I effectiveness-implementation non-inferiority randomized trial in India comparing two active case finding (ACF) strategies among individuals treated for TB and their household contacts. Trials. 2022;23:635. doi: 10.1186/s13063-022-06503-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Trials are provided here courtesy of BMC

RESOURCES